We are live on ! Find out more
JANX icon

Janux Therapeutics

181 hedge funds and large institutions have $1.81B invested in Janux Therapeutics in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 96 increasing their positions, 45 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

295% more call options, than puts

Call options by funds: $17.2M | Put options by funds: $4.35M

113% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 45

1.5% more ownership

Funds ownership: 110.97%112.47% (+1.5%)

16% less funds holding

Funds holding: 216181 (-35)

30% less funds holding in top 10

Funds holding in top 10: 107 (-3)

47% less capital invested

Capital invested by funds: $3.43B → $1.81B (-$1.63B)

66% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 53

Holders
181
Holders Change
-35
Holders Change %
-16.2%
% of All Funds
2.42%
Holding in Top 10
7
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-30%
% of All Funds
0.09%
New
18
Increased
96
Reduced
45
Closed
53
Calls
$17.2M
Puts
$4.35M
Net Calls
+$12.8M
Net Calls Change
-$5.21M

JANX Hedge Fund Activity: Q1 2025 in Review

181 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q1 2025, worth a combined $1.81B — down 47% from $3.43B a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of JANX and 18 opened new positions — a net loss of 35 holders — while 45 trimmed existing stakes and 96 added.

The largest buyer was Janus Henderson Group, adding an estimated $39M. The largest seller was Holocene Advisors, exiting entirely with an estimated $54.3M sold.

  • 181 institutional investors held Janux Therapeutics (JANX) as of Q1 2025, down from 216 in Q4 2024.
  • Funds reported $1.81B of Janux Therapeutics stock for Q1 2025, down 47% quarter-over-quarter.
  • 18 funds opened new Janux Therapeutics positions in Q1 2025 and 53 closed out, a net change of -35 holders.
  • The largest Janux Therapeutics buyer in Q1 2025 was Janus Henderson Group, an estimated $39M added.
  • The largest Janux Therapeutics seller in Q1 2025 was Holocene Advisors, an estimated $54.3M sold.

Based on aggregated 13F filings for Q1 2025.